Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Venetoclax and Capecitabine In Subjects With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy

NCT04274933 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04274933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04274933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Venetoclax and Capecitabine In Subjects With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
May 21, 2020
Completion date
October 8, 2020
Enrollment
4 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cancer